Pre-earnings options volume in Arcutis Biotherapeutics is normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 12.9%, or 0c, after results are released. Median move over the past eight quarters is 6.1%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics announces the JCAD published outcomes of ZORYVE
- Arcutis Biotherapeutics Inc (ARQT) Q1 Earnings Cheat Sheet
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Arcutis Biotherapeutics Welcomes New CFO David Topper
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue